ArticleJAMA internal medicine2013
National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011.
Article in JAMA internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 272 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
272 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Efficacy and safety of vancomycin compared with those of alternative treatments for methicillin-resistant Staphylococcus aureus infections: An umbrella review.Journal of evidence-based medicine · 2024Pooled it
- Efficacy and safety of linezolid compared with other treatments for skin and soft tissue infections: a meta-analysis.Bioscience reports · 2018Pooled it
- A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.Antimicrobial resistance and infection control · 2018Pooled it
- Chlorhexidine and Mupirocin for Clearance of Methicillin-Resistant Staphylococcus aureus Colonization After Hospital Discharge: A Secondary Analysis of the Changing Lives by Eradicating Antibiotic Resistance Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers.The New England journal of medicine · 2019Trial
- Trial
- A Six-Year Retrospective Surveillance of OutpatientInfectious diseases & clinical microbiology · 2026Article
- Factors associated with methicillin resistance in Staphylococcus aureus: a case-case-control analysis of AMR surveillance data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Whole-genome sequencing ofMicrobiology spectrum · 2026Article
- Conserved and context-dependent changes in pathogen and host cell gene expression during Staphylococcus aureus intracellular infection.BMC microbiology · 2026Article
- Antibiotic-resistance plasmid amplified among MRSA cases in an urban jail and its connected communities.Nature communications · 2025Article
- Antibiotic-resistance plasmid amplified among MRSA cases in an urban jail and its connected communities.medRxiv : the preprint server for health sciences · 2025Article
- Trends in Incidence and Epidemiology of Methicillin-ResistantOpen forum infectious diseases · 2025Article
- Antibiotic susceptibility and molecular characterization based on whole-genome sequencing of Staphylococcus aureus causing invasive infection in children and women living in Southwest China during 2018-2023.BMC microbiology · 2025Article
- Associations between total protein, globulin, and nasal Methicillin-ResistantFrontiers in immunology · 2025Article
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria.Frontiers in immunology · 2025Review
- Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000-2021.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Clinical and in vitro models identify distinct adaptations enhancing Staphylococcus aureus pathogenesis in human macrophages.PLoS pathogens · 2024Article
- Antimicrobial Resistance Patterns of Outpatient Staphylococcus aureus Isolates.JAMA network open · 2024Article
212 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
importanceEstimating the US burden of methicillin-resistant Staphylococcus aureus (MRSA) infections is important for planning and tracking success of prevention strategies.
objectiveTo describe updated national estimates and characteristics of health care- and community-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in 2011. DESIGN, SETTING, AND
participantsActive laboratory-based case finding identified MRSA cultures in 9 US metropolitan areas from 2005 through 2011. Invasive infections (MRSA cultured from normally sterile body sites) were classified as health care-associated community-onset (HACO) infections (cultured ≤ 3 days after admission and/or prior year dialysis, hospitalization, surgery, long-term care residence, or central vascular catheter presence ≤ 2 days before culture); hospital-onset infections (cultured >3 days after admission); or community-associated infections if no other criteria were met. National estimates were adjusted using US census and US Renal Data System data. MAIN OUTCOMES AND MEASURES: National estimates of invasive HACO, hospital-onset, and community-associated MRSA infections using US census and US Renal Data System data as the denominator.
resultsAn estimated 80,461 (95% CI, 69,515-93,914) invasive MRSA infections occurred nationally in 2011. Of these, 48,353 (95% CI, 40,195-58,642) were HACO infections; 14,156 (95% CI, 10,096-20,440) were hospital-onset infections; and 16,560 (95% CI, 12,806-21,811) were community-associated infections. Since 2005, adjusted national estimated incidence rates decreased among HACO infections by 27.7% and hospital-onset infections decreased by 54.2%; community-associated infections decreased by only 5.0%. Among recently hospitalized community-onset (nondialysis) infections, 64% occurred 3 months or less after discharge, and 32% of these were admitted from long-term care facilities. CONCLUSIONS AND RELEVANCE: An estimated 30,800 fewer invasive MRSA infections occurred in the United States in 2011 compared with 2005; in 2011 fewer infections occurred among patients during hospitalization than among persons in the community without recent health care exposures. Effective strategies for preventing infections outside acute care settings will have the greatest impact on further reducing invasive MRSA infections nationally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.